An open-label, dose escalation phase 1 study of MLN8237, a novel aurora A kinase inhibitor, in patients with advanced solid tumors.

Trial Profile

An open-label, dose escalation phase 1 study of MLN8237, a novel aurora A kinase inhibitor, in patients with advanced solid tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Sep 2017

At a glance

  • Drugs Alisertib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 11 Sep 2017 Results (n=671) of population PK analysis using patient data from 6 Phase 1, 1 Phase 1/2 and 3 Phase 2 clinical trials published in the British Journal of Clinical Pharmacology
    • 06 Dec 2011 Actual patients number (87) added as reported by ClinicalTrials.gov.
    • 22 Dec 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top